While Galinkin and Whitaker bring equal amounts of passion to their venture, each approaches the future with a different focus. Galinkin brings a medical perspective to the table. He says fellow physicians tell him they are changing the way they practice based on this test.
“If you just look for what you expect to see, that’s what you will see,” Galinkin said. The industry’s standard urine drug screens require physicians to specify the drugs for which they require screening, but the CU Toxicology test sheds light on drug use and abuse physicians would not have otherwise detected.
“If you look for everything—all drugs—there’s a big picture of medical information you get,” Galinkin said. “Doctors are blown away by what they are seeing.”
For drug rehab centers and physicians, a comprehensive and highly accurate test removes the denial and the deception from drug use and addiction.
“This test has good eyesight,” Galinkin said. “If you use us to test, you will get the right answer—no escape.”
When Whitaker looks ahead, he thinks business. He believes the test will find a wide market, largely because it is priced competitively, testing for 112 drugs at the same price that clients traditionally have paid to test for five to 10 drugs. He emphasizes that CU Toxicology is not a straightforward business partnership—it is truly a collaboration. Because it is housed in an internationally recognized research university, CU Toxicology is able to capitalize on immediately available resources—scientific research, state-of-the-art equipment and a practical clinical environment that is the largest and most active of its kind in the Rocky Mountain region.
Collaborating in this manner not only allows access
Copyright©2012 Vocus, Inc.
All rights reserved